Evidence map›Paper›PMID 42426860›Full record

SynthesisBMC nutrition2026

Oral magnesium supplements and insulin resistance in individuals with diabetes and pre-diabetes: an updated systematic review and meta-analysis of randomized controlled trials.

Aryana Amiri, Fateme Seighali, Mohammad Sadra Gholami-Chahkand, Behrooz Jannat, Niloofar Seighali

Abstract readSystematic Review
In one paragraph

Synthesis in BMC nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Aryana AmiriFood and Drug Research Center, Food and Drug Administration, Ministry of Health and Medical Education, Tehran, Iran.
Fateme SeighaliFood and Drug Research Center, Food and Drug Administration, Ministry of Health and Medical Education, Tehran, Iran.ORCID http://orcid.org/0009-0002-2995-7554
Mohammad Sadra Gholami-ChahkandFood and Drug Research Center, Food and Drug Administration, Ministry of Health and Medical Education, Tehran, Iran.ORCID http://orcid.org/0000-0002-5710-2142
Behrooz JannatFood and Drug Research Center, Food and Drug Administration, Ministry of Health and Medical Education, Tehran, Iran. Janatbhr@sina.tums.ac.ir.ORCID http://orcid.org/0000-0001-9208-2709
Niloofar SeighaliFood and Drug Research Center, Food and Drug Administration, Ministry of Health and Medical Education, Tehran, Iran. niloofarseighaly@gmail.com.ORCID https://orcid.org/0000-0002-8862-6029

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDiabetes is a common health challenge. Previous studies have established that diabetes is often associated with low circulating magnesium status. As evidence from randomized controlled trials (RCTs) on the effect of magnesium supplementation on insulin resistance remains inconsistent, and the influence of baseline status is not fully understood, this systematic review and meta-analysis evaluated the effects of magnesium supplements, compared with placebo, on insulin resistance in individuals with diabetes and pre-diabetes.

methodsA comprehensive search based on the PRISMA 2020 guidelines was conducted in PubMed, Web of Science, and Scopus until 24 April 2026. Randomized controlled trials with a population of individuals with diabetes and pre-diabetes that received any magnesium supplements compared to a placebo group, evaluating insulin and the HOMA-IR index as the primary outcome, were included in our study. Secondary outcomes were serum magnesium level, HbA1c, and fasting blood glucose (FBG). We pooled data using a random-effects model to estimate changes in outcomes. Subgroup analyses were conducted based on dosage (> 250 and ≤ 250 mg/day) and follow-up duration (under or over 12 weeks). Meta-regression, publication bias, and sensitivity analysis were performed as well.

resultsFifteen RCTs involving 1,085 participants met the criteria. Overall, the oral magnesium supplementation did not result in a statistically significant change in insulin levels (MD = - 1.73; 95% CI: -3.73 to 0.27; p-value = 0.09) and HOMA-IR (MD = - 0.74; 95% CI: -1.58 to 0.09; p-value = 0.08) in people with diabetes. Similar non-significant findings were observed in individuals with prediabetes (p > 0.05). However, meta-regression analysis demonstrated that baseline insulin level and HOMA-IR index significantly modified the intervention effect (p = 0.01), suggesting differential responsiveness across patient subgroups. No significant associations were observed for baseline HbA1c, fasting blood glucose, magnesium levels, age, or BMI. Subgroup analysis based on doses and duration of follow-up did not change the significance of the result.

conclusionMagnesium supplementation does not appear to improve insulin resistance in individuals with diabetes or prediabetes significantly. However, its effects may depend on baseline insulin status, highlighting the need for targeted interventions in individuals with higher insulin resistance. Future well-designed trials with larger sample sizes are needed to clarify baseline insulin effects.

Indexed as

DiabetesHOMA-IRInsulin resistanceMagnesiumMeta-analysisSupplementSystematic review

Identifiers

PMID42426860
PMCPMC13640189

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.